KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) Invested Capital (2019 - 2025)

Ginkgo Bioworks Holdings' Invested Capital history spans 7 years, with the latest figure at $508.6 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 28.97% year-over-year to $508.6 million; the TTM value through Dec 2025 reached $508.6 million, down 28.97%, while the annual FY2025 figure was $508.6 million, 28.97% down from the prior year.
  • Invested Capital reached $508.6 million in Q4 2025 per DNA's latest filing, down from $559.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.7 billion in Q4 2022 to a low of $356.4 million in Q2 2021.
  • Average Invested Capital over 5 years is $1.1 billion, with a median of $1.0 billion recorded in 2023.
  • Peak YoY movement for Invested Capital: surged 341.13% in 2022, then crashed 44.59% in 2024.
  • A 5-year view of Invested Capital shows it stood at $1.6 billion in 2021, then increased by 10.95% to $1.7 billion in 2022, then crashed by 36.91% to $1.1 billion in 2023, then plummeted by 34.73% to $716.1 million in 2024, then fell by 28.97% to $508.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Invested Capital are $508.6 million (Q4 2025), $559.8 million (Q3 2025), and $613.0 million (Q2 2025).